Diversified Consumer Services
Company Overview of University of Cambridge
University of Cambridge is a public university that offers graduate, postgraduate, and research programs in the field of science, business, social sciences, and law. It offers courses in history, environmental studies, psychology, sociology, zoology, oriental studies, business administration, philosophy, biochemistry, music, engineering, geology, architecture, international relations, and medicine. The institution was founded in 1209 and is based in Cambridge, United Kingdom.
The Old Schools
Cambridge, CB2 1TN
Founded in 1209
Key Executives for University of Cambridge
Regius Professor of Physic
Master of Pembroke College
Head of Institute for Stem Cell Biology
Compensation as of Fiscal Year 2015.
University of Cambridge Key Developments
AstraZeneca, GlaxoSmithKline, Johnson & Johnson and Imperial College London, University of Cambridge and University College London Join For U.K. Drug Development Fund
Jan 27 16
AstraZeneca, GlaxoSmithKline, Johnson & Johnson and three U.K. universities 'Imperial College London, University of Cambridge and University College London (UCL)' are combining to create an almost-$60 million investment fund for drug development. The program, the Apollo Therapeutics Fund, aims to accelerate the translation of academic science into medicines. The partners plan to develop drugs for all therapy areas using systems including small molecules, peptides, proteins, antibodies, and cell and gene therapies. The industrial partners will contribute close to $15 million apiece to the fund over six years. The university partners will each contribute a further $5 million. It is the first time global drug companies and major universities have joined for such a fund, the partners say. Apollo will hire ex-industry scientists to create a drug discovery team that will work with the universities and their technology transfer offices to identify and shape projects. Preclinical research will be advanced to a stage at which it can either be taken forward by one of the industrial partners following an internal bidding process or out-licensed. For projects that become a commercial success, the originating university and its technology transfer office will receive a percentage of commercial revenues or out-licensing fees. The remainder of the income will be divided among the other Apollo partners. By combining funding for promising early-stage therapeutics from the universities with industry expertise, Apollo aims to cut costs and the risk of project failure and accelerate the development of new treatments.
Astrazeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JDJC, Inc. and Imperial College London, University College London and the University of Cambridge Join Forces to Create the Apollo Therapeutics Fund; Appoints Ian Tomlinson as Chairman of Apollo Therapeutics Investment Committee
Jan 25 16
AstraZeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC, Inc. and Imperial College London, University College London and the University of Cambridge have joined forces with a combined £40 million to create the Apollo Therapeutics Fund (‘Apollo’). This pioneering new joint venture will support the translation of ground-breaking academic science from within these universities into innovative new medicines for a broad range of diseases. Each of the three industry partner companies (AstraZeneca UK Limited, Glaxo Group Limited and Johnson & Johnson Innovation-JJDC, Inc.) will contribute £10 million over 6 years to the venture. The technology transfer offices (TTOs) of the three university partners - Imperial Innovations Group plc, Cambridge Enterprise Ltd. Limited and UCL Business PLC - will each contribute a further £3.3 million. The aim of Apollo is to advance academic preclinical research from these universities to a stage at which it can either be taken forward by one of the industry partners following an internal bidding process or be out-licensed. The three industry partners will also provide R&D expertise and additional resources to assist with the commercial evaluation and development of projects. Drug development is extremely complex, costly and lengthy; currently only around 10% of therapies entering clinical trials reach patients as medicines. By combining funding for promising early-stage therapeutics from leading UK universities with a breadth of industry expertise, Apollo aims to share the risk and accelerate the development of important new treatments, while also reducing the cost.
Dr. Ian Tomlinson, former Senior Vice President, Worldwide Business Development and Biopharmaceuticals R&D, for GSK and founder & Chief Scientific Officer of Domantis Limited has been appointed Chairman of the Apollo Therapeutics Investment Committee. Comprising representatives from the six partners, the AIC will make all investment decisions.
University of Cambridge Presents at ICBI's Super Investor 2015, Nov-18-2015 05:10 PM
Nov 15 15
University of Cambridge Presents at ICBI's Super Investor 2015, Nov-18-2015 05:10 PM. Venue: Hotel Okura, Amsterdam, Netherlands. Speakers: John Coates, Research Fellow in Neuroscience and Finance.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|